PortalPublikationenAndrogen receptor expression is a predictive marker in chemo...

Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers

Standard

Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers. / Witzel, Isabell; Graeser, Monika; Karn, Thomas; Schmidt, Markus; Wirtz, Ralph; Schütze, Dina; Rausch, Alma; Jänicke, Fritz; Milde-Langosch, Karin; Müller, Volkmar.

in: J CANCER RES CLIN, Jahrgang 139, Nr. 5, 01.05.2013, S. 809-16.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Witzel, I, Graeser, M, Karn, T, Schmidt, M, Wirtz, R, Schütze, D, Rausch, A, Jänicke, F, Milde-Langosch, K & Müller, V 2013, 'Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers', J CANCER RES CLIN, Jg. 139, Nr. 5, S. 809-16. https://doi.org/10.1007/s00432-013-1382-8

APA

Witzel, I., Graeser, M., Karn, T., Schmidt, M., Wirtz, R., Schütze, D., Rausch, A., Jänicke, F., Milde-Langosch, K., & Müller, V. (2013). Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers. J CANCER RES CLIN, 139(5), 809-16. https://doi.org/10.1007/s00432-013-1382-8

Vancouver

Witzel I, Graeser M, Karn T, Schmidt M, Wirtz R, Schütze D et al. Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers. J CANCER RES CLIN. 2013 Mai 1;139(5):809-16. https://doi.org/10.1007/s00432-013-1382-8

Bibtex

@article{d5738a445476444989dbf5ebc385a93a,
title = "Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers",
abstract = "PURPOSE: The androgen receptor (AR) is intensively discussed as a prognostic and/or predictive marker in breast cancer patients.METHODS: We evaluated the value of AR mRNA expression with the Affymetrix HG-U 133A array in 3 different cohorts: a cohort of breast cancer patients who received adjuvant treatment (cohort A; n = 165), a cohort of untreated breast cancer patients (cohort B; n = 200) and a cohort of chemotherapy-treated breast cancer patients with estrogen receptor (ER)-positive tumors (cohort C; n = 223).RESULTS: AR mRNA expression was associated with lower grading (Grades 1 and 2) as well as ER and progesterone receptor (PgR) positivity in all cohorts. In the treated cohort (cohort A), low androgen receptor expression was associated with shorter event-free survival (OR 2,34, 95 % CI 1.01-5.43, p = 0.047) which was not seen in the untreated cohort B. Subgroup analysis revealed that shorter survival of patients with low AR mRNA expression was observed mainly in the ER-positive subgroup of patients treated with adjuvant chemotherapy. In the validation cohort C we could confirm a benefit of chemotherapy for the group of tumors with high AR mRNA expression (5-year event-free survival (EFS) 74 % versus 57 %, p = 0.013). In this cohort, low AR mRNA expression was associated with shorter event-free survival also in multivariate analysis (OR 2.86, 95 % CI 1.29-6.35, p = 0.010) adjusted for HER2, ki-67, tumor size, age and tumor grade.CONCLUSIONS: We provide evidence that AR expression is associated with chemotherapy responsiveness in ER-positive patients.",
keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Hormonal, Breast Neoplasms, Cohort Studies, Female, Follow-Up Studies, Gene Expression Regulation, Neoplastic, Humans, Middle Aged, Neoplasm Grading, Neoplasm Staging, Prognosis, Receptor, erbB-2, Receptors, Androgen, Receptors, Estrogen, Receptors, Progesterone, Tumor Markers, Biological",
author = "Isabell Witzel and Monika Graeser and Thomas Karn and Markus Schmidt and Ralph Wirtz and Dina Sch{\"u}tze and Alma Rausch and Fritz J{\"a}nicke and Karin Milde-Langosch and Volkmar M{\"u}ller",
year = "2013",
month = may,
day = "1",
doi = "10.1007/s00432-013-1382-8",
language = "English",
volume = "139",
pages = "809--16",
journal = "J CANCER RES CLIN",
issn = "0171-5216",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers

AU - Witzel, Isabell

AU - Graeser, Monika

AU - Karn, Thomas

AU - Schmidt, Markus

AU - Wirtz, Ralph

AU - Schütze, Dina

AU - Rausch, Alma

AU - Jänicke, Fritz

AU - Milde-Langosch, Karin

AU - Müller, Volkmar

PY - 2013/5/1

Y1 - 2013/5/1

N2 - PURPOSE: The androgen receptor (AR) is intensively discussed as a prognostic and/or predictive marker in breast cancer patients.METHODS: We evaluated the value of AR mRNA expression with the Affymetrix HG-U 133A array in 3 different cohorts: a cohort of breast cancer patients who received adjuvant treatment (cohort A; n = 165), a cohort of untreated breast cancer patients (cohort B; n = 200) and a cohort of chemotherapy-treated breast cancer patients with estrogen receptor (ER)-positive tumors (cohort C; n = 223).RESULTS: AR mRNA expression was associated with lower grading (Grades 1 and 2) as well as ER and progesterone receptor (PgR) positivity in all cohorts. In the treated cohort (cohort A), low androgen receptor expression was associated with shorter event-free survival (OR 2,34, 95 % CI 1.01-5.43, p = 0.047) which was not seen in the untreated cohort B. Subgroup analysis revealed that shorter survival of patients with low AR mRNA expression was observed mainly in the ER-positive subgroup of patients treated with adjuvant chemotherapy. In the validation cohort C we could confirm a benefit of chemotherapy for the group of tumors with high AR mRNA expression (5-year event-free survival (EFS) 74 % versus 57 %, p = 0.013). In this cohort, low AR mRNA expression was associated with shorter event-free survival also in multivariate analysis (OR 2.86, 95 % CI 1.29-6.35, p = 0.010) adjusted for HER2, ki-67, tumor size, age and tumor grade.CONCLUSIONS: We provide evidence that AR expression is associated with chemotherapy responsiveness in ER-positive patients.

AB - PURPOSE: The androgen receptor (AR) is intensively discussed as a prognostic and/or predictive marker in breast cancer patients.METHODS: We evaluated the value of AR mRNA expression with the Affymetrix HG-U 133A array in 3 different cohorts: a cohort of breast cancer patients who received adjuvant treatment (cohort A; n = 165), a cohort of untreated breast cancer patients (cohort B; n = 200) and a cohort of chemotherapy-treated breast cancer patients with estrogen receptor (ER)-positive tumors (cohort C; n = 223).RESULTS: AR mRNA expression was associated with lower grading (Grades 1 and 2) as well as ER and progesterone receptor (PgR) positivity in all cohorts. In the treated cohort (cohort A), low androgen receptor expression was associated with shorter event-free survival (OR 2,34, 95 % CI 1.01-5.43, p = 0.047) which was not seen in the untreated cohort B. Subgroup analysis revealed that shorter survival of patients with low AR mRNA expression was observed mainly in the ER-positive subgroup of patients treated with adjuvant chemotherapy. In the validation cohort C we could confirm a benefit of chemotherapy for the group of tumors with high AR mRNA expression (5-year event-free survival (EFS) 74 % versus 57 %, p = 0.013). In this cohort, low AR mRNA expression was associated with shorter event-free survival also in multivariate analysis (OR 2.86, 95 % CI 1.29-6.35, p = 0.010) adjusted for HER2, ki-67, tumor size, age and tumor grade.CONCLUSIONS: We provide evidence that AR expression is associated with chemotherapy responsiveness in ER-positive patients.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Agents, Hormonal

KW - Breast Neoplasms

KW - Cohort Studies

KW - Female

KW - Follow-Up Studies

KW - Gene Expression Regulation, Neoplastic

KW - Humans

KW - Middle Aged

KW - Neoplasm Grading

KW - Neoplasm Staging

KW - Prognosis

KW - Receptor, erbB-2

KW - Receptors, Androgen

KW - Receptors, Estrogen

KW - Receptors, Progesterone

KW - Tumor Markers, Biological

U2 - 10.1007/s00432-013-1382-8

DO - 10.1007/s00432-013-1382-8

M3 - SCORING: Journal article

C2 - 23392859

VL - 139

SP - 809

EP - 816

JO - J CANCER RES CLIN

JF - J CANCER RES CLIN

SN - 0171-5216

IS - 5

ER -